Compare
Exagen Inc. vs Personalis, Inc. vs Biodesix Inc vs CapForce Inc.
| Latest fiscal year | Exagen Inc. XGN | Personalis, Inc. PSNL | Biodesix Inc BDSX | CapForce Inc. CFOR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $66.58M | $69.65M | $88.50M | $30.20M |
| Revenue growth (YoY) | +19.7% | -17.7% | +24.1% | +481.2% |
| Gross margin | 58.3% | 22.7% (computed) | n/a | n/a |
| Operating margin | -21.1% | -126.4% | -31.5% | 79.6% |
| Net margin | -30.0% | -116.7% | -39.8% | 78.2% |
| Net income | -$19.95M | -$81.27M | -$35.27M | $23.62M |
| EPS (Diluted) | -$0.93 | -$0.91 | -$4.67 | $2.32 |
| Operating cash flow | -$13.62M | -$74.95M | -$23.27M | -$1.18M |
| Free cash flow | -$14.27M | -$79.45M | -$23.53M | -$1.23M |
| Cash & equivalents | $32.22M | $124.25M | $18.99M | $531.3K |
| Total assets | $58.02M | $334.16M | $87.48M | $38.06M |
| Total liabilities | $40.57M | $72.98M | $89.94M | $6.20M |
| Shareholders' equity | $17.45M | $261.19M | -$2.46M | $31.86M |
| Return on year-end equity | -114.3% | -31.1% | n/a | 74.1% |
| Shares outstanding | 22.91M | 102.48M | 8.25M | 10.15M |
Revenue, most recent five fiscal years
| Fiscal year | Exagen Inc. | Personalis, Inc. | Biodesix Inc | CapForce Inc. |
|---|---|---|---|---|
| Latest | $66.58M Ended 2025-12-31 | $69.65M Ended 2025-12-31 | $88.50M Ended 2025-12-31 | $30.20M Ended 2025-12-31 |
| 1 year earlier | $55.64M Ended 2024-12-31 | $84.61M Ended 2024-12-31 | $71.32M Ended 2024-12-31 | $5.20M Ended 2024-12-31 |
| 2 years earlier | $52.55M Ended 2023-12-31 | $73.48M Ended 2023-12-31 | $49.09M Ended 2023-12-31 | $3.42M Ended 2023-12-31 |
| 3 years earlier | $45.56M Ended 2022-12-31 | $65.05M Ended 2022-12-31 | $38.21M Ended 2022-12-31 | $2.61M Ended 2022-12-31 |
| 4 years earlier | $48.30M Ended 2021-12-31 | $85.49M Ended 2021-12-31 | $54.51M Ended 2021-12-31 | $4.31M Ended 2021-12-31 |